Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1046P represents a processed pseudogene derived from the U6 small nuclear RNA family. The canonical U6 small nuclear RNA (snRNA) is a highly conserved non-coding RNA that is an essential component of the spliceosome, facilitating the removal of introns from pre-mRNA during RNA splicing[1][2]. However, RNU6-1046P is specifically annotated as a pseudogene, meaning it is an inactive, non-functional copy that does not contribute to spliceosomal activity and does not encode a protein or functional RNA molecule. Many U6 snRNA pseudogenes exist in vertebrate genomes, generated largely by retrotransposition events; they serve as molecular fossils and are not considered functional biological entities or therapeutic targets[3]. As such, RNU6-1046P is not recognized as a receptor, enzyme, or other typical drug target and has no known biological function, disease association, or therapeutic relevance[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 1046, pseudogene (RNU6-1046P).